fluorometholone

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: fluorometholone
• 英文别名: flumetholone；Efflumidex；FML S.O.P.；oxylone；Flucon；eflone；17-acetyl-9-fluoro-11,17-dihydroxy-6,10,13-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one
• 化学式: C₂₂H₂₉FO₄
• 分子量: 376.468
• InChiKey: FAOZLTXFLGPHNG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  27
• 可旋转键数：
  1
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.73
• 拓扑面积：
  74.6
• 氢给体数：
  2
• 氢受体数：
  5

ADMET

毒理性

• 在妊娠和哺乳期间的影响

◉ 母乳喂养期间使用概述：目前没有关于氟甲松眼用制剂在哺乳期间使用的信息。由于眼部吸收有限，眼用氟甲松不太可能对哺乳婴儿产生任何不良反应。为了显著减少使用眼药水后到达母乳中的药物量，可以在眼角对泪囊施加压力1分钟或更长时间，然后用吸收性纸巾移除多余的溶液。 ◉ 对哺乳婴儿的影响：截至修订日期，没有找到相关的已发布信息。 ◉ 对泌乳和母乳的影响：截至修订日期，没有找到相关的已发布信息。

◉ Summary of Use during Lactation:No information is available on the ophthalmic use of fluorometholone during breastfeeding. Because absorption from the eye is limited, ophthalmic fluorometholone would not be expected to cause any adverse effects in breastfed infants. To substantially diminish the amount of drug that reaches the breastmilk after using eye drops, place pressure over the tear duct by the corner of the eye for 1 minute or more, then remove the excess solution with an absorbent tissue. ◉ Effects in Breastfed Infants:Relevant published information was not found as of the revision date. ◉ Effects on Lactation and Breastmilk:Relevant published information was not found as of the revision date.

来源:Drugs and Lactation Database (LactMed)

文献信息

• CORTICOSTEROID CONJUGATES AND USES THEREOF
  申请人：Teicher Martin H.

  公开号：US20100056488A1

  公开（公告）日：2010-03-04

  The invention features corticosteroids conjugated to either a charged group or a bulky group in a manner that resists in vivo cleavage, the resulting conjugate is a peripherally acting steroid with reduced activity in the central nervous system. The invention provides a method for treating a patient having an inflammatory disease by administering to the patient a corticosteroid conjugate.
• Oligomer-Corticosteroid Conjugates
  申请人：Zhang Wen

  公开号：US20100286107A1

  公开（公告）日：2010-11-11

  The invention provides corticosteroids that are chemically modified by covalent attachment of a water soluble oligomer. A compound of the invention, when administered by any of a number of administration routes, exhibits a reduced biological membrane crossing rate as compared to the biological membrane crossing rate of the corticosteroid not attached to the water soluble oligomer.
• OLIGOMER-CORTICOSTEROID CONJUGATES
  申请人：NAKTAR THERAPEUTICS

  公开号：US20140309398A1

  公开（公告）日：2014-10-16

  The invention provides corticosteroids that are chemically modified by covalent attachment of a water-soluble oligomer. A compound of the invention, when administered by any of a number of administration routes, exhibits different properties compared to the properties of the corticosteroid not attached to the water-soluble oligomer.
• US8796248B2
  申请人：——

  公开号：US8796248B2

  公开（公告）日：2014-08-05
• [EN] OLIGOMER-CORTICOSTEROID CONJUGATES<br/>[FR] CONJUGUÉS D'OLIGOMÈRES ET CORTICOSTÉROÏDES
  申请人：NEKTAR THERAPEUTICS AL CORP

  公开号：WO2009045539A2

  公开（公告）日：2009-04-09

  The invention provides corticosteroids that are chemically modified by covalent attachment of a water soluble oligomer. A compound of the invention, when administered by any of a number of administration routes, exhibits a reduced biological membrane crossing rate as compared to the biological membrane crossing rate of the corticosteroid not attached to the water soluble oligomer.